Vimarsana
Biggest News Aggregation in the World

Page 37 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

Alzheimer's Drug Meant To Slow Disease Becomes More Accessible to Americans After Getting FDA's Full Approval | HNGN - Vimarsana News

Alzheimer's Drug Meant To Slow Disease Becomes More Accessible to Americans After Getting FDA's Full Approval | HNGN

The FDA approved Leqembi for people with early Alzheimer's disease on Thursday, making it easier for older adults to obtain the first drug to slow memory and thinking issues.

Source: hngn.com
Leqembi: FDA grants full approval for Alzheimer's drug that has shown to modestly slow cognitive decline - Vimarsana News

Leqembi: FDA grants full approval for Alzheimer's drug that has shown to modestly slow cognitive decline

The FDA granted full approval to Leqembi, an Alzheimer's drug, clearing the way for Medicare and other insurance to begin paying for the treatment.

Source: abc7.com
Getinge recieves US FDA 510(k) clearance for Servo-air® Lite - Vimarsana News

Getinge recieves US FDA 510(k) clearance for Servo-air® Lite

/PRNewswire/ -- "We are happy to broaden our ventilator product offering for the US market", says Elin Frostehav, President Acute Care Therapies at Getinge....

FDA Grants Rare Pediatric Disease Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy - Vimarsana News

FDA Grants Rare Pediatric Disease Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy

/PRNewswire/ -- NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Rare Pediatric Disease Designation to NS-089/NCNP-02...

FDA approval for first Alzheimer's drug slowing disease progression - Vimarsana News

FDA approval for first Alzheimer's drug slowing disease progression

The first and only approved anti-amyloid Alzheimer's Disease (AD) treatment shown to reduce the rate of disease progression and slow cognitive impairment has been granted approval by the FDA.